Autres langues Medicus Pharma Ltd.

Actions

MDCX

CA58471K1030

Marché Fermé - Toronto S.E. Autres places de cotation 18:17:21 24/06/2024			Varia. 5j.	Varia. 1 janv.
1,67 ^CAD	-1,76%		-5,65%	-16,50%

21/03	Medicus Pharma Ltd. annonce la réception de commentaires de la Food and Drug Administration des États-Unis	CI
05/03	Medicus Pharma Ltd. annonce la nomination d'Erica Monaco au poste de chef de l'exploitation	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Medicus Pharma Files Registration Statement for Proposed Initial Public Offering in the United States	29/05
Medicus Pharma Ltd. Announces Filing of Registration Statement for Proposed Initial Public Offering in the United States	29/05
Medicus Pharma Plans Private Placement for Clinical Development Acceleration	07/05
Medicus Pharma Ltd. Announces Closing of Private Placement of Convertible Notes	04/05
Canadian Investment Regulatory Organization Trade Resumption - MDCX	25/04
Medicus Pharma Ltd. Announces Proposed Private Placement of Convertible Notes	25/04
Canadian Investment Regulatory Organization Trading Halt - MDCX	25/04
Medicus Pharma Ltd. announced a financing transaction	25/04
Medicus Pharma says U.S. FDA has provided comments on Phase 2 Clinical Protocol of SKNJCT-003	28/03
Medicus Pharma Ltd. Announces the Receipt of Comments from the U.S Food and Drug Administration	21/03
Medicus Pharma Ltd. Receives FDA Comments on Phase 2 Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin	21/03
Medicus Pharma Names COO	05/03
Medicus Pharma Ltd. Announces Appointment of Erica Monaco as Chief Operating Officer	05/03
Medicus Pharma Ltd. Announces the Appointment of Erica Monaco as Chief Operating Officer	05/03
Medicus Pharma Ltd. Publishes the Amended Clinical Study Report from the SKNJCT-001 Phase 1 Safety and Tolerability Study	15/02
Medicus Pharma Ltd. Publishes Phase 1 Clinical Study Report Demonstrating Safety & Tolerability in All Participants with Basal Cell Carcinoma	15/02
Medicus Pharma Ltd. Announces the Filing of a Final Base Shelf Prospectus	25/01
Medicus Pharma Ltd. Announces Listing on Frankfurt Stock Exchange	18/01
Medicus Pharma Ltd. Announces the Submission to the United States Food and Drug Administration A Phase 2 Investigational New Drug Clinical Protocol (SKNJCT-003)	03/01
Medicus Pharma Ltd. Submits to the FDA Phase 2 IND Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin	03/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Medicus Pharma Ltd.

Actions

MDCX

CA58471K1030

Autres langues

Filtres